CVE:RX - Biosyent Stock Price, News & Analysis

Today's Range N/A
50-Day Range
C$6.25
MA: C$6.59
C$7.50
52-Week Range N/A
Volume1,196 shs
Average Volume8,564 shs
Market CapitalizationC$87.02 million
P/E Ratio16.58
Dividend YieldN/A
BetaN/A
BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used in agriculture. BioSyent Inc. distributes its products to pharmacies and hospitals. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Toronto, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-2060013

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$21.56 million
Book ValueC$1.90 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$87.02 million
Next Earnings Date8/23/2019 (Confirmed)
OptionableNot Optionable

Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.


Biosyent (CVE:RX) Frequently Asked Questions

What is Biosyent's stock symbol?

Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How were Biosyent's earnings last quarter?

Biosyent Inc. (CVE:RX) announced its quarterly earnings results on Wednesday, May, 29th. The company reported $0.07 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.01. The business had revenue of $4.48 million for the quarter, compared to analysts' expectations of $4.90 million. View Biosyent's Earnings History.

When is Biosyent's next earnings date?

Biosyent is scheduled to release their next quarterly earnings announcement on Friday, August 23rd 2019. View Earnings Estimates for Biosyent.

What price target have analysts set for RX?

1 brokerages have issued twelve-month price objectives for Biosyent's stock. Their forecasts range from C$7.50 to C$7.50. On average, they expect Biosyent's stock price to reach C$7.50 in the next twelve months. View Analyst Price Targets for Biosyent.

What is the consensus analysts' recommendation for Biosyent?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biosyent in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biosyent.

Has Biosyent been receiving favorable news coverage?

Media headlines about RX stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Biosyent earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Biosyent.

Who are some of Biosyent's key competitors?

What other stocks do shareholders of Biosyent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biosyent investors own include Aurora Cannabis (ACB), Sibanye Gold (SBGL), Turquoise Hill Resources (TRQ), Turtle Beach (HEAR), Cross Timbers Royalty Trust (CRT), Nokia Oyj (NOK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), FireEye (FEYE) and Flex (FLEX).

Who are Biosyent's key executives?

Biosyent's management team includes the folowing people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Kevin Wilson, VP of Community Health Bus.
  • Mr. Sharan Raghubir MBA, Director of the Hospital Bus. Unit - Biosyent Pharma Inc
  • Mr. Alfred D'Souza, Advisor
  • Mr. Robert March, VP of Fin. & CFO

How do I buy shares of Biosyent?

Shares of RX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is Biosyent?

Biosyent has a market capitalization of C$87.02 million and generates C$21.56 million in revenue each year. View Additional Information About Biosyent.

What is Biosyent's official website?

The official website for Biosyent is http://www.biosyent.com/.

How can I contact Biosyent?

Biosyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.


MarketBeat Community Rating for Biosyent (CVE RX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Biosyent and other stocks. Vote "Outperform" if you believe RX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel